心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Stroke：全身性血管瘤患者颅内动脉瘤患病率

2019-11-18 xing.T MedSci原创

全身性血管瘤颅内动脉瘤患病率
关注

由此可见，OVAD患者IA患病率高于对照组。因此，我们可能会将动脉瘤视为一种全身性疾病，并且必须对其病理生理学进行深入研究。

大多数动脉瘤是全身性疾病的病灶表现。一些报告表明遗传和环境因素可能在其发病机理中起作用。近日，心血管疾病领域权威杂志Stroke上发表了一篇研究文章，该研究旨在评估大型其他全身性血管动脉瘤和夹层动脉瘤（OVAD）患者队列中颅内动脉瘤（IA）患病率，并确定该人群中IA的潜在危险因素。

研究人员将OVAD定义为不包括主动脉夹层和动脉瘤的全身性血管动脉瘤。研究人员从韩国国民健康保险局的人群研究队列中提取了110万名患者组成队列，该队列包含了几乎所有的医疗数据，包括诊断代码、操作和个人信息。研究人员使用χ2或Fisher精确检验分析了与OVAD状态有关的IA患病率。

在OVAD个人中，同时诊断为IA的患者占25.7％（261/1017）。OVAD患者并发IA的比值比为56.31（95％CI为48.821-64.949；P=0.000）。血脂异常的OVAD患者患有IA的可能性增加约7倍（校正后的比值比为7.7[95％CI为6.59-9.01]；P=0.000）。高血压、糖尿病、老年（>60岁）和男性同时并发IA的几率分别增加了5.89、3.48、1.83和1.35倍。社会经济或残疾状况的亚组分析显示所有组中IA患病率均显著增加。关于发作时间的不确定性以及缺乏疾病严重程度和亚型的详细信息阻碍了更多结论性结果。

由此可见，OVAD患者IA患病率高于对照组。因此，我们可能会将动脉瘤视为一种全身性疾病，并且必须对其病理生理学进行深入研究。 

原始出处：

Jihye Song.et al.Prevalence of Intracranial Aneurysms in Patients With Systemic Vessel Aneurysms A Nationwide Cohort Study.stroke.2019.https://www.ahajournals.org/doi/10.1161/STROKEAHA.119.027285

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1250650, encodeId=cee1125065057, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 20 13:22:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348299, encodeId=db7313482999e, content=<a href='/topic/show?id=1eaf89e26d3' target=_blank style='color:#2F92EE;'>#血管瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89726, encryptionId=1eaf89e26d3, topicName=血管瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Nov 20 13:22:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375521, encodeId=63d73e552189, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Nov 19 06:38:54 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375518, encodeId=f69d3e5518f9, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Nov 19 05:25:56 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2019-11-20 xinmeili

    #患病率#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1250650, encodeId=cee1125065057, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 20 13:22:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348299, encodeId=db7313482999e, content=<a href='/topic/show?id=1eaf89e26d3' target=_blank style='color:#2F92EE;'>#血管瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89726, encryptionId=1eaf89e26d3, topicName=血管瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Nov 20 13:22:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375521, encodeId=63d73e552189, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Nov 19 06:38:54 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375518, encodeId=f69d3e5518f9, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Nov 19 05:25:56 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2019-11-20 clmlylxy

    #血管瘤#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1250650, encodeId=cee1125065057, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 20 13:22:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348299, encodeId=db7313482999e, content=<a href='/topic/show?id=1eaf89e26d3' target=_blank style='color:#2F92EE;'>#血管瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89726, encryptionId=1eaf89e26d3, topicName=血管瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Nov 20 13:22:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375521, encodeId=63d73e552189, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Nov 19 06:38:54 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375518, encodeId=f69d3e5518f9, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Nov 19 05:25:56 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2019-11-19 1e1c07bdm01(暂无匿称)

    好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1250650, encodeId=cee1125065057, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 20 13:22:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348299, encodeId=db7313482999e, content=<a href='/topic/show?id=1eaf89e26d3' target=_blank style='color:#2F92EE;'>#血管瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89726, encryptionId=1eaf89e26d3, topicName=血管瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Nov 20 13:22:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375521, encodeId=63d73e552189, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Nov 19 06:38:54 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375518, encodeId=f69d3e5518f9, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Nov 19 05:25:56 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2019-11-19 yjs木玉

    好好好好好好

    0